Although gene alteration in our report was different from that in these clinical trials mentioned above, it may be a good reference and attempt for EGFR-mutated NSCLC patients with ERBB2 amplification adopting the combination therapy with afatinib plus bevacizumab. Here, EGFR is linked to non-small cell lung carcinoma.